Prophylactic vaccines are potent activators of monocyte-derived dendritic cells and drive effective anti-tumor responses in melanoma patients at the cost of toxicity
/in Dendritic Cells, International Publications, Malignant Melanoma /von 2016-02-10 / Cancer Immunol. Immunother. 2016 Mar;65(3):327-39Type I-polarized BRAF-pulsed dendritic cells induce antigen-specific CD8+ T cells that impact BRAF-mutant murine melanoma
/in Dendritic Cells, International Publications, Malignant Melanoma /von 2016-02-01 / Melanoma Res. 2016 Feb;26(1):1-11Effective Clinical Responses in Metastatic Melanoma Patients after Vaccination with Primary Myeloid Dendritic Cells
/in Dendritic Cells, International Publications, Malignant Melanoma /von 2015-12-28 / Clin. Cancer Res. 2016 05;22(9):2155-66Sensitivity of Human Malignant Melanoma Cell Lines to Newcastle Disease Virus
/in International Publications, Malignant Melanoma, Newcastle Disease Virus /von 2015-10-01 / Anticancer Res. 2015 Oct;35(10):5401-6Prophylactic Dendritic Cell-Based Vaccines Efficiently Inhibit Metastases in Murine Metastatic Melanoma
/in Dendritic Cells, International Publications, Malignant Melanoma /von 2015-09-01 / PLoS ONE 2015;10(9):e0136911Phase III multicenter trial of eltrapuldencel-T: Autologous dendritic cells loaded with irradiated autologous tumor cells (DC-TC) in granulocyte-macrophage colony stimulating factor (GM-CSF) in patients with metastatic melanoma (INTUS trial).
/in Dendritic Cells, International Publications, Malignant Melanoma /von 2015-06-01 / J Clin Oncol 33, 2015 (suppl; abstr TPS9082)Cancer immunotherapy. A dendritic cell vaccine increases the breadth and diversity of melanoma neoantigen-specific T cells
/in Dendritic Cells, International Publications, Malignant Melanoma /von 2015-04-02 / Science 2015 May;348(6236):803-8Recombinant Newcastle Disease virus Expressing IL15 Demonstrates Promising Antitumor Efficiency in Melanoma Model
/in International Publications, Malignant Melanoma, Newcastle Disease Virus /von 2014-11-24 / Technol. Cancer Res. Treat. 2015 Oct;14(5):607-15Radiotherapy as an immunological booster in patients with metastatic melanoma or renal cell carcinoma treated with high-dose Interleukin-2: evaluation of biomarkers of immunologic and therapeutic response
/in Dendritic Cells, Hypernephroma, International Publications, Malignant Melanoma /von 2014-09-23 / J Transl Med 2014 Sep;12:262
IMMUN-ONKOLOGISCHES ZENTRUM KÖLN
Hohenstaufenring 30–32
50674 Köln | Deutschland
T: +49 (0)221 – 420 399 25
E-Mail: info@iozk.de
Hohenstaufenring 30–32
50674 Köln | Deutschland
T: +49 (0)221 – 420 399 25
E-Mail: info@iozk.de